Peer-reviewed veterinary case report
Stem cell treatment for dog with immune thrombocytopenia and diabetes
By Jang, Hee-Won et al.·Published in Veterinary research communications·2025·VIP Animal Medical Center, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Therapeutic application of canine adipose tissue-derived mesenchymal stromal cells in a dog with refractory immune-mediated thrombocytopenia, with diabetic ketoacidosis, and gastrointestinal bleeding induced by immunosuppressive treatment.
- Species:
- dog
Plain-English summary
A 7-year-old dog with immune-mediated thrombocytopenia (ITP) was struggling with severe bleeding and complications from long-term medication, including diabetic ketoacidosis. After traditional treatments failed and caused serious side effects, the dog received stem cell therapy using its own fat-derived cells. This innovative treatment was given through eight intravenous sessions over two months. Remarkably, the dog's ITP improved, and it no longer needed the problematic medication, leading to a resolution of the side effects.
People also search for: dog immune-mediated thrombocytopenia treatment · stem cell therapy for dogs · diabetic ketoacidosis in dogs · dog gastrointestinal bleeding causes
Abstract
Refractory immune-mediated thrombocytopenia (ITP) in dogs is a condition with a poor prognosis due to the poor response to immunosuppressive therapy and the adverse effects of long-term drug administration. This case report describes the successful management of refractory ITP using stem cell therapy in a dog that experienced severe side effects from immunosuppressive treatment. The patient experienced recurrent relapses when prednisolone (PDS) tapering was attempted during conventional immunosuppressive therapy, necessitating prolonged use of PDS; this led to complications, such as diabetic ketoacidosis and chronic gastrointestinal bleeding. In this case, the dog was treated with canine adipose tissue-derived mesenchymal stromal cells (cAT-MSCs) administered intravenously at four-week intervals for eight sessions. Following MSC therapy, refractory ITP was successfully treated without PDS, and the side effects associated with prolonged use of PDS and multiple immunosuppressants were resolved. Although further investigations are needed for the clinical application of cAT-derived MSCs in ITP, cAT-MSC injections could be an alternative treatment option for refractory ITP in veterinary medicine.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40875161/